Circulation analysis finds SUMMIT benefits spread across symptoms, function and medication burden

A companion analysis of the SUMMIT trial found that tirzepatide, sold as Zepbound, produced consistent improvements across a wide range of heart failure measures in people with heart failure with preserved ejection fraction (HFpEF) and obesity, not just the two main endpoints reported earlier ^[1][2].

The expanded analysis, published in Circulation, looked at 731 patients with class II to IV heart failure, an ejection fraction of 50% or higher, and a body mass index of 30 or above ^[1]. Participants were randomly assigned to receive tirzepatide, titrated up to a weekly injection of 15 mg, or a placebo, on top of their usual heart failure treatment, for a median of 104 weeks ^[1][2].

Patients getting tirzepatide walked farther, felt better and needed fewer heart failure drugs than those on placebo. At 52 weeks, the tirzepatide group's 6-minute walk distance rose by 18.3 meters compared with placebo, and their EQ-5D-5L quality-of-life score improved by 0.06 points ^[1][2]. Their New York Heart Association class, a standard measure of how limited a patient is by heart failure symptoms, shifted to a more favorable level, with a proportional odds ratio of 2.26 ^[1][2]. Patients also needed fewer heart failure medications, a difference that was statistically significant ^[1][2].

To capture the overall picture across all these measures at once, researchers used a hierarchical composite based on death, worsening heart failure events, and 52-week changes in symptom scores and walking distance. On this combined measure, tirzepatide had a win ratio of 1.63, meaning that when a tirzepatide patient and a placebo patient were compared, the tirzepatide patient came out ahead about 63% more often than the reverse ^[1][2]. Across all the different ways researchers defined worsening heart failure or death as a combined outcome, tirzepatide's hazard ratios ranged from 0.41 to 0.67, meaning the risk of these events was lower on the drug in every version tested ^[1][2].

Why it matters for patients

HFpEF with obesity is a difficult condition to treat. Patients often have severe fatigue and breathlessness, and previous heart failure drugs approved for other forms of the disease, such as certain blood pressure and diabetes medications, have generally produced only modest improvements in symptoms and exercise capacity for this specific group ^[1]. This analysis suggests tirzepatide's benefit is not limited to a single lab value or hospital visit count. It touches how far patients can walk, how they rate their own quality of life, their formal symptom class, and how many other heart failure pills they need ^[1][2].

That breadth matters because a person living with HFpEF often cares less about a single statistic than about whether they can do daily activities and whether their symptom burden and pill count go down. The consistency across these different measures — all pointing the same direction — supports the idea that the effect is broad rather than a fluke tied to one test ^[1].

Still, this was a clinical trial population selected for significant baseline symptoms and functional limits, with 53% having had a worsening heart failure event in the prior year ^[1]. Whether these findings apply the same way to people with milder symptoms or different health profiles is not addressed in this analysis.

What happens next

The SUMMIT trial's primary results were published previously, and this expanded analysis appeared in Circulation alongside an editorial discussing tirzepatide's potential role in obesity-related HFpEF ^[1][2]. The sources do not specify a timeline for any regulatory decision related to these findings or for when broader clinical guidelines might incorporate this data, so that remains not yet known.